nad has been researched along with Hematologic Malignancies in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biniecka, P; Bruzzone, S; Caffa, I; Carmona, AT; Duchosal, MA; Fratta, S; Moreno-Vargas, AJ; Nahimana, A; Nencioni, A; Piacente, F; Robina, I | 1 |
| Bai, JF; Belotti, A; Biniecka, P; Bruzzone, S; Cea, M; Decosterd, LA; Desfontaine, V; Duchosal, MA; Joussot, J; Majjigapu, SR; Matsumoto, S; Nahimana, A; Nencioni, A; Piacente, F; Spaggiari, D; Thoueille, P; Vogel, P | 1 |
| Arruga, F; Deaglio, S; Guerra, G; Vaisitti, T | 1 |
| Andrianova, EL; Antoch, MP; Chernov, MV; Chernova, OB; Gudkov, AV; Gupta, M; Haber, M; Henderson, MJ; Joshi, S; Kazyulkin, D; Komarov, PG; Kononov, E; Korotchkina, L; Krasnov, P; Lock, RB; Middlemiss, S; Norris, MD; Polinsky, A; Somers, K; Tian, Y; Toshkov, I; Veith, J; Vujcic, S | 1 |
| Cagnetta, A; Cea, M; Gobbi, M; Lemoli, RM; Soncini, D | 1 |
| Attinger, A; Aubry, D; Dawson, KM; Duchosal, MA; Dupuis, M; Greaney, P; Ireson, C; Nahimana, A; Thougaard, AV; Tjørnelund, J | 1 |
1 review(s) available for nad and Hematologic Malignancies
| Article | Year |
|---|---|
Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets.
Topics: 5'-Nucleotidase; Adenosine Triphosphate; ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Animals; Antigens, CD; Apyrase; GPI-Linked Proteins; Hematologic Neoplasms; Humans; NAD; Nucleotidases | 2019 |
5 other study(ies) available for nad and Hematologic Malignancies
| Article | Year |
|---|---|
Synthesis and structure-activity relationship of new nicotinamide phosphoribosyltransferase inhibitors with antitumor activity on solid and haematological cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytokines; Enzyme Inhibitors; Hematologic Neoplasms; Humans; Leukemia; NAD; Nicotinamide Phosphoribosyltransferase; Structure-Activity Relationship | 2023 |
Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies.
Topics: Animals; Cell Line, Tumor; Cytokines; Enzyme Inhibitors; Hematologic Neoplasms; Humans; Mice; NAD; Nicotinamide Phosphoribosyltransferase; Reactive Oxygen Species | 2023 |
OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Proliferation; Cytokines; Female; Hematologic Neoplasms; High-Throughput Screening Assays; Humans; Male; Mice; Mice, Inbred C57BL; NAD; Niacin; Nicotinamide Phosphoribosyltransferase; Pyrazoles; Pyridines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Exploiting tumor vulnerabilities: NAD(+)-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; NAD; Nicotinamide Phosphoribosyltransferase | 2016 |
The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies.
Topics: Acrylamides; Animals; Antineoplastic Agents; Cell Death; Cytokines; Dose-Response Relationship, Drug; Hematologic Neoplasms; HL-60 Cells; Humans; Jurkat Cells; K562 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; NAD; Nicotinamide Phosphoribosyltransferase; Piperidines; Tumor Cells, Cultured; U937 Cells; Xenograft Model Antitumor Assays | 2009 |